Sign In
Buy ALT
$2.87
-0.0300 (-1.03%)
At Close: Jun 03, 2026
Is the Options Market Predicting a Spike in Altimmune (ALT) Stock?
12:58pm, Friday, 15'th May 2020
Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
12:00am, Friday, 15'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 14)
Allogene Therapeutics Inc (...
6 Stocks To Watch: Co-Diagnostics, Inovio, Progyny, Translate Bio, Upwork...
12:00am, Thursday, 14'th May 2020
Stocks Analysis by Harry Boxer covering: Overstockcom Inc, PGT Innovations Inc, Creative Realities Inc, United Natural Foods Inc. Read Harry Boxer's latest article on Investing.com
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update
09:18pm, Wednesday, 13'th May 2020
GAITHERSBURG, Md., May 13, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31,.
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update
09:18pm, Wednesday, 13'th May 2020
GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020 an
Stocks Slide About 2%, Ending NASDAQ's Six-Day Run
01:15pm, Wednesday, 13'th May 2020
Stocks Slide About 2%, Ending NASDAQ's Six-Day Run
Merck's KEYTRUDA Superior to Brentuximab Vedotin , a Standard of Care, in Patients with Classical Hodgkin Lymphoma in Head-to-Head Phase 3 Trial
Altimmune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of Directors
11:00am, Tuesday, 12'th May 2020
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Diane Jorkasky, M.D. to its Board of Directors. Diane K. Jorkasky, M.D. FACP is a highly regarded
Introducing Altimmune (NASDAQ:ALT), The Stock That Collapsed 98%
12:11pm, Saturday, 09'th May 2020
Altimmune, Inc. (NASDAQ:ALT) shareholders will doubtless be very grateful to see the share price up 73% in the last...
Altimmune to Announce First Quarter 2020 Financial Results on May 14
11:00am, Friday, 08'th May 2020
GAITHERSBURG, Md., May 08, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the.
These 23 companies are working on coronavirus treatments or vaccines — here’s where things stand
06:50pm, Wednesday, 06'th May 2020
A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel...
Loan dispute puts iProsperity subsidiary in receivership
08:02am, Sunday, 03'rd May 2020
The dispute relates to loans provided to iProsperity Underwriting by Alan Caratti's Agricultural Land Trust and funded through its debenture program.
$8.8+ Billion Biodefense Industry Insight, 2027: Impact of COVID-19 on the Global Market
03:45pm, Friday, 24'th Apr 2020
The "Biodefense - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
The "Biodefense - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
Global Biodefense Market is Expected to Reach $8.85 Billion by 2027
09:00pm, Tuesday, 21'st Apr 2020
According to Stratistics MRC, the Global Biodefense System market is accounted for $5.47 billion in 2018 and is expected to reach $8.85 billion by 2027 growing at a CAGR of 5.5% during the forecast pe
